Latest Headlines

Online Exclusive

Hospitals Struggling to Break Even on CAR T-Cell Therapy

Since the first chimeric antigen receptor (CAR) T-cell therapies were approved by the U.S. Food and Drug Administration (FDA) in 2017, U.S. hospitals have...

Proposed 2020 Budget Would Slash Cancer Funding

On March 11, President Donald Trump released his proposed fiscal year 2020 budget, which included a 12-percent cut to the U.S. Department of Health...

Cover Story

Predatory Publishing: The Dark Side of the Open-Access Movement

In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker side of scientific publishing: predatory publishing. This segment of the OA publishing movement is characterized by publishers that “unprofessionally exploit” the gold OA model (in which the final version of a manuscript is made freely available on publication), primarily for profit, according to Jeffrey Beall, MSLS, one of the most vigilant watchdogs of predatory publishing, and operator of the website Scholarly Open Access. Sometimes called “vanity presses,” these entities publish practically any materials that come their way, as long as authors are willing to pay a submission and publication fee. Critics – and they are legion...

Clinical News

Latest Videos

Pulling Back the Curtain: Dan Pollyea, MD, MS

In more from our interview with Dan Pollyea, MD, MS, he shares what he learned from growing up watching his father practice medicine and the simple...

Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism

Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...

Ravulizumab: A New Treatment Option for PNH?

Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

A Rapid, Inexpensive Screening Test for Sickle Cell Disease in Uganda

Erik Serrao, PhD, discusses the HemoTypeSC test, which provides a rapid, cost-effective screening method for sickle cell disease in newborns living in limited-resource settings.

On Location

A Safer Conditioning Regimen for Patients With Bone Marrow Failure and Short Telomeres?

A study of patients with bone marrow failure (BMF) and short telomeres found that a...

Salvage Transplant Versus Continuous Therapy: Insights From the Myeloma ReLApsE Trial

For patients with multiple myeloma (MM) that has relapsed following autologous hematopoietic cell transplantation (AHCT),...

Venetoclax Plus R-CHOP Improves Outcomes in BCL2-Positive DLBCL

For the substantial portion of patients with diffuse large B-cell lymphoma (DLBCL) with overexpression of...

Rituximab-Lenalidomide Combo Superior to Rituximab Alone in Relapsed/Refractory Indolent NHL

For patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL), adding lenalidomide to rituximab treatment improved response...

Evaluating Ixazomib Regimens in Patients With Newly Diagnosed Myeloma

Two studies presented at the 2018 ASH Annual Meeting explored the use the oral proteasome...

An ASH Annual Meeting Post-Vivum

“So, what did you learn from ASH?” asked my advisor a couple of weeks after...
Advertisement

Sign Up for our enewsletter!

Subscribe to our newsletter to receive the latest news, updates and online exclusive content.

8,802FollowersFollow
7,937SubscribersSubscribe
WIB_icon

Can a Virtual Benign Hematology Consult Improve Access to and Quality of Care?

A multidisciplinary team of researchers developed a virtual benign hematology consultative service that can potentially reduce the time it takes a specialist to examine...

Aggressive Imatinib Dose Escalation Shows No Improvement Over Standard Escalation in CML

For patients with newly diagnosed chronic myeloid leukemia (CML), aggressive dose escalation of imatinib failed to improve response and survival rates compared with a...

New Policy Takes Aim at “Secret” Hospital and Insurer Negotiations

In a proposed rule, the U.S. Department of Health and Human Services (HHS) announced it is considering requiring U.S. hospitals and insurers to publicize...

Opioid Prescriptions Down, But Pain May Be Up

Since the Centers for Disease Control and Prevention (CDC) issued strict guidelines to curb inappropriate patterns of opioid prescription, the prescribing rate has declined....

Women Awarded Smaller First-Time NIH Grants Than Men

First-time National Institutes of Health (NIH) grants awarded to female principal investigators were substantially smaller than those awarded to male principal investigators, according to...